Affiliation:
1. Unitat de Suport a la Recerca of Tarragona, Institut Universitari d'Investigacio en Atencio Primaria Jordi Gol (IDIAP Jordi Gol), Tarragona, Spain
2. Primary Health Care Service Camp de Tarragona, Tarragona, Spain
3. Primary Care Research Institute Jordi Gol. Barcelona, Spain
4. Information System for the Improvement of Research in Primary Care (SIDIAP), Primary Care Research Institute Jordi Gol, Universitat Autonoma de Barcelona, Barcelona, Spain
Abstract
Background
Recent published data on pneumococcal vaccination coverages among adults are scarce.
Aim
To update on pneumococcal vaccination uptakes among middle-aged and older adults in Catalonia.
Methods
We conducted a population-based retrospective observational study including 2,057,656 individuals ≥ 50 years old assigned to primary care centres managed by the Catalonian Health Institute on 1 January 2017 (date of data collection). An institutional clinical research database (SIDIAP) was used to classify persons by vaccination status for both 23-valent pneumococcal polysaccharide (PPsV23) and 13-valent pneumococcal conjugate (PCV13) vaccines, as well as to identify underlying risk conditions.
Results
Overall, 796,879 individuals (38.7%) had received PPsV23 and 13,607 (0.7%) PCV13. PPsV23 coverage increased with age: 9.2% (95,409/1,039,872) in 50–64 year olds, 63.1% (434,408/688,786) in 65–79 year olds and 81.2% (267,062/328,998) in ≥ 80 year olds (p < 0.001). PCV13 coverage also increased with age, although percentages were smaller in all age strata (4,250/1,039,872: 0.4%; 6,005/688,786: 0.9% and 3,352/328,998: 1.0%, respectively; p < 0.001). By sex, no substantial coverage differences were observed. Considering publically funded target groups for PPsV23 vaccination in Catalonia (i.e. < 65 year olds with at least one risk factor, plus all adults aged ≥ 65 years), PPsV23 coverage reached 52.8% (771,722/1,462,261) in our study population. Regarding PCV13 publicly funded targets (i.e. all-age immunocompromised persons), PCV13 coverage was 3.3% (6,617/202,348). By risk conditions, the highest PPsV23 coverage appeared in congestive heart failure (51,909/63,596; 81.6%), chronic renal disease (122,791/158,726; 77.4%) and chronic bronchitis/emphysema (96,453/132,306; 72.9%). Maximum PCV13 coverage appeared in cirrhosis (294/7,957; 3.7%), chronic renal disease (5,633/158,726; 3.5%) and chronic bronchitis/emphysema (2,859/132,306; 2.2%).
Conclusion
Pneumococcal vaccination coverages in Catalonian adults are suboptimal, especially for PCV13.
Publisher
European Centre for Disease Control and Prevention (ECDC)
Subject
Virology,Public Health, Environmental and Occupational Health,Epidemiology
Reference33 articles.
1. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features.;Örtqvist;Semin Respir Crit Care Med,2005
2. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practice (ACIP).;MMWR Morb Mortal Wkly Rep,1997
3. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older.;MMWR Morb Mortal Wkly Rep,2012
4. Vaccination Coverage Among Adults Aged 65 and Over: United States, 2015.;Norris;NCHS Data Brief,2017